Patents by Inventor Tina Garyantes
Tina Garyantes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230382896Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.Type: ApplicationFiled: August 3, 2023Publication date: November 30, 2023Applicant: Linnaeus Therapeutics, Inc.Inventors: Christopher NATALE, Patrick MOONEY, Tina GARYANTES, Wayne LUKE
-
Patent number: 11760749Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.Type: GrantFiled: February 25, 2021Date of Patent: September 19, 2023Assignee: Linnaeus Therapeutics, Inc.Inventors: Christopher Natale, Patrick T. Mooney, Tina Garyantes, Wayne Luke
-
Publication number: 20220089576Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.Type: ApplicationFiled: May 24, 2021Publication date: March 24, 2022Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
-
Publication number: 20220033385Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.Type: ApplicationFiled: February 25, 2021Publication date: February 3, 2022Applicant: Linnaeus Therapeutics, Inc.Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
-
Patent number: 10934277Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.Type: GrantFiled: November 13, 2019Date of Patent: March 2, 2021Assignee: LINNAEUS THERAPEUTICS, INC.Inventors: Christopher Natale, Patrick T. Mooney, Tina Garyantes, Wayne Luke
-
Publication number: 20200140417Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.Type: ApplicationFiled: November 13, 2019Publication date: May 7, 2020Applicant: Linnaeus Therapeutics, Inc.Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
-
Publication number: 20200024262Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.Type: ApplicationFiled: July 22, 2019Publication date: January 23, 2020Applicant: Linnaeus Therapeutics, Inc.Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
-
Publication number: 20170304306Abstract: Provided herein are methods for treating or preventing prediabetes or diabetes, or maintaining or lowering blood or plasma glucose or maintaining or lowering blood or plasma glycated hemoglobin comprising administering to a subject in need thereof a therapeutically effective amount of a compound selectively inhibiting NaV1.7. In particular, provided herein are processes for the preparation of and intermediates used in the preparation of compounds selectively inhibiting NaV 1.Type: ApplicationFiled: September 8, 2015Publication date: October 26, 2017Applicant: CHROMOCELL CORPORATIONInventors: Yanlin WANG-FISCHER, Olga BABICH, Tina GARYANTES, Robert Z. LUO, Srinivasan P. Venkatachalan
-
Patent number: 9458118Abstract: Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I or compounds of Formula I?: In particular, provided herein are processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions comprising, and therapeutic methods comprising administering such compounds. In particular, provided herein are compounds for the treatment of pain and diabetes.Type: GrantFiled: January 13, 2016Date of Patent: October 4, 2016Assignee: Chromocell CorporationInventors: Olga Babich, Tina Garyantes, Robert Z. Luo, David J. Palling, Srinivasan P. Venkatachalan, Yanlin Wang-Fischer
-
Publication number: 20160221974Abstract: Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I or compounds of Formula I?: In particular, provided herein are processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions comprising, and therapeutic methods comprising administering such compounds. In particular, provided herein are compounds for the treatment of pain and diabetes.Type: ApplicationFiled: September 9, 2014Publication date: August 4, 2016Applicant: CHROMOCELL CORPORATIONInventors: Olga BABICH, Tina GARYANTES, Robert Z. LUO, David J. PALLING, Srinivasan P. VENKATACHALAN, Yanlin WANG-FISCHER
-
Publication number: 20160130239Abstract: Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I or compounds of Formula I?: In particular, provided herein are processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions comprising, and therapeutic methods comprising administering such compounds. In particular, provided herein are compounds for the treatment of pain and diabetes.Type: ApplicationFiled: January 13, 2016Publication date: May 12, 2016Applicant: CHROMOCELL CORPORATIONInventors: Olga BABICH, Tina GARYANTES, Robert Z. LUO, David J. PALLING, Srinivasan P. VENKATACHALAN, Yanlin WANG-FISCHER
-
Publication number: 20100248224Abstract: The present invention provides methods for the detection of agents that modify the formation of DNA fragmentation in cells. The disclosed methods are configured in an assay format amendable to high throughput screening applications.Type: ApplicationFiled: June 20, 2007Publication date: September 30, 2010Applicant: SANOFI-AVENTISInventors: Tina Garyantes, Zhuyin Li, Yongping Yan, Justin Anthony Yu, Asher Zilberstein
-
Patent number: 7276206Abstract: Methods of identifying activators and inhibitors of voltage-gated ion channels are provided in which the methods employ electrical field stimulation of the cells in order to manipulate the open/close state transition of the voltage-gated ion channels. This allows for more convenient, more precise experimental manipulation of these transitions, and, coupled with efficient methods of detecting the result of ion flux through the channels, provides methods that are especially suitable for high throughput screening.Type: GrantFiled: July 12, 2002Date of Patent: October 2, 2007Assignee: Merck & Co., Inc.Inventors: Paul R. Augustine, Randal M. Bugianesi, Gary S. Kath, Owen B. McManus, Paul B. Bennett, Tina A. Garyantes, John P. Imredy
-
Publication number: 20050164161Abstract: Methods of identifying activators and inhibitors of voltage-gated ion channels are provided in which the methods employ electrical field stimulation of the cells in order to manipulate the open/close state transition of the voltage-gated ion channels. This allows for more convenient, more precise experimental manipulation of these transitions, and, coupled with efficient methods of detecting the result of ion flux through the channels, provides methods that are especially suitable for high throughput screening.Type: ApplicationFiled: July 12, 2002Publication date: July 28, 2005Inventors: Paul Augustine, Randal Bugianesi, Gary Kath, Owen McManus, Paul Bennett, Tina Garyantes, John Imredy
-
Patent number: 6565813Abstract: Microtiter-like plates containing virtual wells formed by an arrangement of relatively hydrophilic domains within relatively hydrophobic fields are provided. Assay mixtures are confined to the hydrophilic domains of the virtual wells by the edges of the hydrophobic fields. The use of virtual wells allows one to perform homogeneous and capture and wash high throughput screening assays with assay mixtures having volumes on the order of about 100 nl to 10 &mgr;l. Virtual wells also provide a means of easily moving fluids, which is particularly useful for simultaneous additions needed for kinetic studies and flash detection and washing. Methods for controlling evaporation during the dispensing of reagents as well as during incubation of high throughput screening utilizing microtiter-like plates containing virtual wells are also provided.Type: GrantFiled: August 2, 2000Date of Patent: May 20, 2003Assignee: Merck & Co., Inc.Inventor: Tina Garyantes